<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01970176</url>
  </required_header>
  <id_info>
    <org_study_id>11-004644</org_study_id>
    <secondary_id>HL76611-07P3</secondary_id>
    <nct_id>NCT01970176</nct_id>
  </id_info>
  <brief_title>Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Systolic Cardiomyopathy (Aim2)</brief_title>
  <acronym>Aim2</acronym>
  <official_title>Define in Preclinical Systolic Dysfunction (PSD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of 12 weeks of chronic PDEV inhibition with Tadalafil versus placebo&#xD;
      on basal cardiorenal and humoral function and on the integrated cardiorenal and humoral&#xD;
      response to acute sodium loading in subjects with preclinical systolic dysfunction (PSD) and&#xD;
      renal (kidney) dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At the consent visit a blood draw will be done also a the 6 minute walk will be done to&#xD;
      determine eligibility and a physical exam along with vital signs, height and weight will be&#xD;
      done. Twenty-four hour urine collection will be obtained one day prior to the active study&#xD;
      day.&#xD;
&#xD;
      Prior to initiation of the study, subjects will be stabilized for at least one week on a no&#xD;
      added salt diet (120 milliequivalents of sodium/salt per day (mEq Na/day) which will be&#xD;
      maintained throughout the study period.&#xD;
&#xD;
      Subjects will be admitted to the Clinical Research Unit (CRU)on the evening before the active&#xD;
      study day. They will be able to order a no-added salt meal and will not have anything to eat&#xD;
      after midnight until the last renal clearance blood draw the next day. Bladder scan will be&#xD;
      carried out to assess for urine retention. On the active study day, subjects take their&#xD;
      medications upon awakening, however, diabetics will hold their diabetic medications until&#xD;
      after the last renal clearance test then they will be able to order a regular diet meal and&#xD;
      take their diabetic medications. Subjects will be asked to drink 5ml/Kg (milliliters per&#xD;
      kilogram of body weight) of water to insure sufficient urinary flow. A priming dose&#xD;
      (calculated according to body size) of Iothalamate, to measure glomerular filtration rate&#xD;
      (GFR) and para-amino-hippurate (PAH) to measure effective renal plasma flow (ERPF) is&#xD;
      infused, followed by a constant rate IV sustaining dose (calculated according to estimated&#xD;
      kidney function) of Iothalamate or PAH. The subjects will be asked to empty their bladder&#xD;
      spontaneously every thirty minutes. Throughout the study, at the end of each 30-minute&#xD;
      clearance period, subjects will be asked to drink an amount of water equivalent to the sum of&#xD;
      the blood losses and the urinary flow. After an equilibration period of 45 minutes, a&#xD;
      30-minute baseline renal clearance will be carried out.&#xD;
&#xD;
      Blood pressure will be measured at 20-minute intervals by using automatic blood pressure&#xD;
      cuff, and heart rate will be continuously monitored by electrocardiography. Echocardiography&#xD;
      will be performed during these baseline clearances to determine left atrial (LA) and Left&#xD;
      Ventricular (LV)volumes and systolic and diastolic function.&#xD;
&#xD;
      After the baseline clearance the acute saline load will be administered (normal saline 0.9%&#xD;
      0.25 ml/kg/min for 1 hour). During the 1 hour saline load, one 30-minute clearance (as&#xD;
      outlined above) will be repeated with the subjects in supine position after which a second&#xD;
      30-minute clearance will be repeated with the subject sitting or the head of the bed up. As&#xD;
      above, blood samples are collected midway during each clearance and urine samples are&#xD;
      obtained every 30 minutes. Echocardiography will be repeated immediately after the end of the&#xD;
      saline infusion.&#xD;
&#xD;
      At the completion of the baseline renal clearance periods and response to acute sodium load,&#xD;
      subjects will be randomized to Tadalafil or placebo. Subjects will be randomized in a 2:1&#xD;
      fashion.&#xD;
&#xD;
      All subjects will take oral Tadalafil (5 mg) or placebo once a day. The blood pressure will&#xD;
      be checked prior to administering the drug.Thereafter, both blood pressure and heart rate&#xD;
      will continue to be monitored for the next 4 hours. If after the first dose of study drug if&#xD;
      patient's systolic blood pressure is &lt; 85 mmHg systolic and has symptoms of hypotension e.g.&#xD;
      lightheadedness, dizziness, feeling faint, blurred vision, the study drug will be stopped&#xD;
      however the subject will continue in the study. After 2 hours if blood pressure is &gt;95&#xD;
      systolic then give 1 more (5 mg) of Tadalafil or placebo and monitor blood pressure for 2&#xD;
      hours. If blood pressure is &gt;95 then dismiss subject on 2 (5 mg) tabs of tadalafil or&#xD;
      placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of&#xD;
      Tadalafil or placebo.&#xD;
&#xD;
      Patients will then be dismissed. Subjects will also have access to a 24-hour phone number&#xD;
      should they have any questions or develop any side effects. Subjects will return after one&#xD;
      week (+ or - 4 days) for electrolyte check. They will also receive a weekly phone call to&#xD;
      review status.&#xD;
&#xD;
      At 2 weeks (± 5 days) from dismissal if blood pressure is&gt; 100 than add 1 (5 mg) tab of&#xD;
      Tadalafil or placebo to make a total of 3 (5mg) tabs of Tadalafil or placebo.&#xD;
&#xD;
      At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg)&#xD;
      Tadalafil or placebo.&#xD;
&#xD;
      After six weeks( + or - 5 days) , subjects will repeat blood draw for safety labs (total&#xD;
      blood count and electrolytes). For patients who do not live more than 25 miles away we will&#xD;
      try to arrange this visit with the patient's local physician.&#xD;
&#xD;
      At the end of the twelve-week study period (+ or - 8 days), subjects will be admitted to the&#xD;
      Clinical Research Unit the afternoon prior to the renal clearance study. Echocardiography,&#xD;
      renal clearance, humoral determination and acute saline load will be performed in the same&#xD;
      manner as the baseline study. Subjects will also perform a 24-hour urine collection the day&#xD;
      prior to their return visit for determination of sodium excretion and creatinine clearance.&#xD;
      Subjects will be dismissed after the renal clearance study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2014</start_date>
  <completion_date type="Actual">September 2019</completion_date>
  <primary_completion_date type="Actual">September 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Urinary Sodium Excretion</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in total urinary sodium excretion as measured by MEq/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Glomerular Filtration Rate (GFR)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in total GFR as measured by ml/1.72m2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary Cyclic Guanosine 3',5'-Monophosphate (cGMP) Hormone Excretion</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Change in total urinary cGMP hormone excretion as measured by pmol/min</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Cardiomyopathy</condition>
  <condition>Renal Impairment</condition>
  <arm_group>
    <arm_group_label>Tadalafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject will receive Tadalafil daily for a total of 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subject will receive Placebo daily for a total of 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil</intervention_name>
    <description>Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
    <arm_group_label>Tadalafil</arm_group_label>
    <other_name>Tadalafil 5mg tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A total of 39 patients with PSD as defined by an ejection fraction of less than 40%,&#xD;
             no clinical signs or symptoms of congestive heart failure, a minimal distance on&#xD;
             6-minute walk of equal or &gt;450 meters will be recruited and calculated creatinine&#xD;
             clearance of equal or less than 90 ml/min and greater than 30 ml/min, using the&#xD;
             (MDRD-measurement of renal dysfunction, formula) assessed within the past 24 months.&#xD;
             If the subject is not able to walk 450 meters due to pain in hips and knees and not&#xD;
             fatigue or shortness of breath than they will still qualify for the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or anticipated future need for nitrate therapy&#xD;
&#xD;
               -  Systolic blood pressure &lt; 90 mmHg or &gt; 180 mm Hg&#xD;
&#xD;
               -  Diastolic blood pressure &lt; 40 mmHg or &gt; 100 mmHg&#xD;
&#xD;
               -  Patients taking alpha antagonists or cytochrome P450 3A4 inhibitors&#xD;
                  (ketoconazole, itraconazole, erythromycin, saquinavir, cimetidine or serum&#xD;
                  proteases inhibitors for HIV) who cannot be taken off these medications for the&#xD;
                  duration of the study.&#xD;
&#xD;
               -  Patients taking the following selective alpha blockers and who are unable to stop&#xD;
                  for the duration of the study;&#xD;
&#xD;
               -  Alfuzosin&#xD;
&#xD;
               -  Prazosin&#xD;
&#xD;
               -  Doxazosin&#xD;
&#xD;
               -  Tamsulosin&#xD;
&#xD;
               -  Terazosin&#xD;
&#xD;
               -  Silodosin&#xD;
&#xD;
               -  Patients with retinitis pigmentosa, previous diagnosis of nonischemic optic&#xD;
                  neuropathy, untreated proliferative retinopathy or unexplained visual disturbance&#xD;
&#xD;
               -  Patients with sickle cell anemia, multiple myeloma, leukemia or penile&#xD;
                  deformities placing them at risk for priapism (angulation, cavernosal fibrosis or&#xD;
                  Peyronie's disease)&#xD;
&#xD;
               -  Patients with an allergy to iodine.&#xD;
&#xD;
               -  Patients on PDEV inhibition for pulmonary hypertension&#xD;
&#xD;
               -  Patients on PDEV inhibition for erectile dysfunction who are not willing to stop&#xD;
                  the medication for the duration of the study&#xD;
&#xD;
               -  Valve disease (&gt; moderate aortic or mitral stenosis; &gt; moderate aortic or mitral&#xD;
                  regurgitation)&#xD;
&#xD;
               -  Obstructive Hypertrophic cardiomyopathy&#xD;
&#xD;
               -  Infiltrative or inflammatory myocardial disease (amyloid, sarcoid)&#xD;
&#xD;
               -  Pericardial disease&#xD;
&#xD;
               -  Have experienced a myocardial infarction or unstable angina, or have undergone&#xD;
                  percutaneous transluminal coronary angiography (PTCA) or coronary artery bypass&#xD;
                  grafting (CABG) within 60 days prior to consent, or requires either PTCA or CABG&#xD;
                  at the time of consent&#xD;
&#xD;
               -  Severe congenital heart diseases&#xD;
&#xD;
               -  Sustained ventricular tachycardia or ventricular fibrillation within 14 days of&#xD;
                  screening&#xD;
&#xD;
               -  Second or third degree heart block without a permanent cardiac pacemaker&#xD;
&#xD;
               -  Stroke within 3 months of screening or other evidence of significantly&#xD;
                  compromised Central Nervous System (CNS) perfusion&#xD;
&#xD;
               -  Hemoglobin &lt;9 g/dL&#xD;
&#xD;
               -  Patients with severe liver disease (AST &gt; 3x normal, alkaline phosphatase or&#xD;
                  bilirubin &gt; 2x normal)&#xD;
&#xD;
               -  Serum sodium of &lt; 125 mEq/dL or &gt; 150 mEq/dL&#xD;
&#xD;
               -  Serum potassium of &lt; 3.2 mEq/dL or &gt; 5.9 mEq/dL&#xD;
&#xD;
               -  Prior diagnosis of intrinsic renal diseases including renal artery stenosis of &gt;&#xD;
                  50%&#xD;
&#xD;
               -  Peritoneal or hemodialysis within 90 days or anticipation that dialysis or&#xD;
                  ultrafiltration of any form will be required during the study period&#xD;
&#xD;
               -  Less than 21 years of age&#xD;
&#xD;
               -  Pregnant or nursing women.&#xD;
&#xD;
               -  Women of child bearing potential who do not have a negative pregnancy test at&#xD;
                  study entry and who are not using effective contraception&#xD;
&#xD;
               -  Non-cardiac condition limiting life expectancy to less than one year, per&#xD;
                  physician judgment&#xD;
&#xD;
               -  Other acute or chronic medical conditions or laboratory abnormality which may&#xD;
                  increase the risks associated with study participation or may interfere with&#xD;
                  interpretation of the data&#xD;
&#xD;
               -  Received an investigational drug within 1 month prior to dosing&#xD;
&#xD;
               -  In the opinion of the investigator is unlikely to comply with the study protocol&#xD;
                  or is unsuitable for any reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Horng H Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 22, 2013</study_first_submitted>
  <study_first_submitted_qc>October 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2013</study_first_posted>
  <results_first_submitted>July 1, 2020</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2020</results_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Horng Chen</investigator_full_name>
    <investigator_title>MD, Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tadalafil</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT01970176/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tadalafil</title>
          <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tadalafil</title>
          <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="58" upper_limit="73"/>
                    <measurement group_id="B2" value="64" lower_limit="54" upper_limit="73"/>
                    <measurement group_id="B3" value="67" lower_limit="56" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Urinary Sodium Excretion</title>
        <description>Change in total urinary sodium excretion as measured by MEq/min</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Sodium Excretion</title>
          <description>Change in total urinary sodium excretion as measured by MEq/min</description>
          <units>MEq/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5" lower_limit="-4.2" upper_limit="77.2"/>
                    <measurement group_id="O2" value="25.1" lower_limit="2.9" upper_limit="61.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Glomerular Filtration Rate (GFR)</title>
        <description>Change in total GFR as measured by ml/1.72m2</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glomerular Filtration Rate (GFR)</title>
          <description>Change in total GFR as measured by ml/1.72m2</description>
          <units>ml/1.72m2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.2" lower_limit="-30.0" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-18.5" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary Cyclic Guanosine 3',5'-Monophosphate (cGMP) Hormone Excretion</title>
        <description>Change in total urinary cGMP hormone excretion as measured by pmol/min</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tadalafil</title>
            <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Urinary Cyclic Guanosine 3',5'-Monophosphate (cGMP) Hormone Excretion</title>
          <description>Change in total urinary cGMP hormone excretion as measured by pmol/min</description>
          <units>pmol/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-71.1" lower_limit="-266.0" upper_limit="-41.0"/>
                    <measurement group_id="O2" value="51.6" lower_limit="-198.0" upper_limit="237.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.32</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from baseline to end of study, approximately 13 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tadalafil</title>
          <description>Subject received Tadalafil daily for a total of 12 weeks&#xD;
Tadalafil: Tadalafil 5 mg tablet. Daily. Tadalafil dose varies from 5 mg to 20 mg for 12 weeks. If blood pressure is &gt;95 then subject dismissed from the Clinical Research Unit (CRU) on 2 (5 mg) tabs of tadalafil or placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tab of Tadalafil. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 (5 mg) tab of Tadalafil to make a total of 3 (5mg) tabs of Tadalafil. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 (5 mg) tablets of Tadalafil.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subject received Placebo daily for a total of 12 weeks&#xD;
Placebo: Placebo tablet. Daily. Placebo tablets made to match appearance of 5mg Tadalafil tablets. Placebo dose varies from 5 mg to 20 mg (1 to 4 tablets) for 12 weeks. If blood pressure is &gt;95 then subject dismissed from CRU on 2 tabs of placebo. If blood pressure is between 90 - 95 mmHg systolic, then dismiss on 1 (5 mg) tablet of placebo. At 2 weeks (± 5 days) if blood pressure is&gt; 100 than add 1 tab of placebo to make a total of 3 tablets of placebo. At 4 weeks(± 5 days) if blood pressure is &gt; 100 add 1 (5 mg) tab to make a total of 4 tablets of placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Indigestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Horng H. Chen, M.D.</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-8896</phone>
      <email>chen.horng@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

